← 返回

脂质纳米颗粒包裹的编码肿瘤特异性毒素蛋白的 mRNA 选择性靶向癌细胞并刺激 T 细胞浸润

英文原题:Lipid Nanoparticle-Encapsulated mRNAs Encoding Tumor-Specific Toxin Proteins Selectively Target Cancer Cells and Stimulate T-cell Infiltration.

查看英文原题

Lipid Nanoparticle-Encapsulated mRNAs Encoding Tumor-Specific Toxin Proteins Selectively Target Cancer Cells and Stimulate T-cell Infiltration.

PubMed 2025/10/01(内容时间) Cancer Res Q1 · IF 22.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

未经标记:基于mRNA的治疗代表了一种改善多种疾病结局的潜在策略。肿瘤特异性毒素可能是基于mRNA的癌症治疗的理想候选者。在本研究中,我们研究了脂质纳米颗粒(LNP)包裹的mRNA编码肿瘤特异性毒素蛋白中性粒细胞弹性蛋白酶(ELANE)或猪胰腺弹性蛋白酶(PPE)的抗肿瘤潜力。在体外,用ELANE或PPE mRNA-LNP处理可选择性地杀死各种癌症细胞类型,但不杀死非癌细胞。此外,给予ELANE和PPE mRNA-LNP显著抑制了体内肿瘤生长,并诱导了CD8+ T细胞浸润,而在小鼠中未观察到急性毒性。来自不同物种的几种其他弹性蛋白酶也对癌细胞有效。总之,这些数据支持进一步开发肿瘤特异性毒素蛋白mRNA-LNP作为癌症的治疗策略。意义:用脂质纳米颗粒包裹的mRNA编码肿瘤特异性毒素蛋白进行治疗可减少肿瘤生长并激活抗肿瘤免疫,为治疗对免疫治疗耐药或无反应的肿瘤提供了一种替代方法。

展开英文摘要原文

UNLABELLED: Treatment with mRNA-based therapeutics represents a potential strategy for improving outcomes of diverse diseases. Tumor-specific toxins might represent ideal candidates for mRNA-based cancer therapeutics. In this study, we investigated the antitumor potential of lipid nanoparticle (LNP)-encapsulated mRNA encoding the tumor-specific toxin protein neutrophil elastase (ELANE) or porcine pancreatic elastase (PPE). Treatment with either ELANE or PPE mRNA-LNP selectively killed various cancer cell types but not noncancer cells in vitro.

Furthermore, ELANE and PPE mRNA-LNP administration significantly inhibited tumor growth in vivo and induced CD8+ T-cell infiltration, whereas no acute toxicity was observed in mice. Several additional elastases from different species were also effective against cancer cells.

Altogether, these data support further development of tumor-specific toxin protein mRNA-LNP as a therapeutic strategy for cancer. SIGNIFICANCE: Treatment with lipid nanoparticle-encapsulated mRNA encoding tumor-specific toxin proteins reduces tumor growth and activates antitumor immunity, providing an alternative approach for treating tumors that are resistant or unresponsive to immunotherapy.

论文信息

作者
Zhou R、Han L、Wang J、Ma L、Zhang T、Qi T、Liu M、Dong Y
单位
Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China.China
文献类型
非美国政府资助研究
期刊
Cancer research2025 Oct 1
原文标识
PubMed 40759030 · DOI 10.1158/0008-5472.CAN-24-3914